Lake Street Initiates Coverage of OncoCyte (OCX) with Buy Recommendation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 29 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Analyst Coverage and Price Forecast: Lake Street initiated coverage of OncoCyte with a Buy recommendation, projecting a 30.67% upside in the stock price, with an average target of $4.21/share based on recent performance.
Institutional Ownership Changes: There has been a notable increase in institutional ownership of OncoCyte, with several funds increasing their stakes, while AWM Investment reduced its holdings significantly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
